Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

TCA Cycle Inhibition By Cpi-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)

Timothy S Pardee, MD PhD, Lance D Miller, PhD, Kristin Pladna, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, Dianna Howard, MD, Megan Manuel, MSN, Sarah Dralle, MSN, Susan Lyerly, PA-C, Bayard L Powell, MD

Blood (2016) 128 (22): 4062.

https://doi.org/10.1182/blood.V128.22.4062.4062

Published: 2016

Journal Articles

The Mitochondrial Metabolism Inhibitor Cpi-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone Is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML)

Timothy Pardee, MD PhD, Kristin Pladna, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, Dianna Howard, MD, Megan Manuel, MSN, Sarah Dralle, MSN, David D Hurd, MD, Susan Lyerly, PA-C, Bayard L Powell, MD

Blood (2015) 126 (23): 2556.

https://doi.org/10.1182/blood.V126.23.2556.2556

Published: 2015

Journal Articles

Feasibility of a Symptom-Adapted Physical Activity Intervention during Induction Chemotherapy for Older Adults with Acute Myeloid Leukemia (AML)

Heidi D. Klepin, MD MS, Janet Tooze, PhD, Timothy Pardee, MD PhD, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, Dianna Howard, MD, Wendy Demark-Wahnefried, PhD, Shannon Mihalko, PhD, William Jack Rejeski, PhD, Bayard L. Powell, MD, Stephen Kritchevsky, PhD

Blood (2015) 126 (23): 2102.

https://doi.org/10.1182/blood.V126.23.2102.2102

Published: 2015

Journal Articles

Is Rituximab Needed With High Dose Chemotherapy and Autologous Stem Cell Transplant When Patients With Non-Hodgkin’s Lymphoma Have Been Exposed To It?

Zartash Gul, MD, Stephan Anderson, MD, Stacey Slone, Saurabh Chhabra, MD, Gregory Monohan, MD, Dianna Howard, MD, Amber Lawson, PharmD, John Hayslip, MD

Blood (2013) 122 (21): 5552.

https://doi.org/10.1182/blood.V122.21.5552.5552

Published: 2013

Journal Articles

MRP1 Plays a Role in Regulating Hematopoietic Stem Cell Oxidative Stress and Differentiation Via MRP1-Dependent Gsh Efflux

Cassandra J Reiling, B.A., Dianna Howard, MD, Christian M Paumi, Ph.D.

Blood (2012) 120 (21): 1223.

https://doi.org/10.1182/blood.V120.21.1223.1223

Published: 2012

Journal Articles

A Phase 2 Study of Bortezomib Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid Leukemia: A Children's Oncology Group (COG) Study

Terzah M. Horton, MD, PhD, John Perentesis, MD, Alan S. Gamis, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, M.A., Jennifer Ballard, CRA, Kathleen Adlard, RN, Dianna Howard, MD, Franklin O. Smith, MD, Jeffrey A. Moscow, MD

Blood (2012) 120 (21): 3580.

https://doi.org/10.1182/blood.V120.21.3580.3580

Published: 2012

Journal Articles

A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients

Sucha Nand, MD, Megan Othus, PhD, John E. Godwin, MD, MS, Cheryl L Willman, MD, Thomas Norwood, Harry Paul Erba, MD, PhD, Dianna Howard, MD, Steven E. Coutre, MD, Frederick R. Appelbaum, MD

Blood (2012) 120 (21): 3584.

https://doi.org/10.1182/blood.V120.21.3584.3584

Published: 2012

Journal Articles

A Phase I Study of the Combination of Azacitidine, Cyclophosphamide, Vincristine, and Rituximab in Relapsed and Refractory Lymphoma

Jessica J. Moss, MD, Dianna Howard, MD, Emily Van Meter, Ph.D., John Hayslip, MD

Blood (2011) 118 (21): 1624.

https://doi.org/10.1182/blood.V118.21.1624.1624

Published: 2011

Journal Articles

A Phase I study using Bortezomib with Weekly Idarubicin for the Treatment of Elderly (>60 YEARS) and Relapsed Patients with Acute Myeloid Leukemia (AML)

Dianna Howard, MD, Jane Liesveld, MD, Gordon L. Phillips, II, MD, Monica L. Guzman, PhD, Craig T. Jordan, PhD

Blood (2008) 112 (11): 2953.

https://doi.org/10.1182/blood.V112.11.2953.2953

Published: 2008

Journal Articles

Gelclair® for the Treatment of Chemotherapy-Induced Stomatitis in Transplant and Hematology Patients: An Interim Analysis.

Susanne E. Liewer, PharmD, Keith A. Hecht, PharmD, Courtney F. Smith, PharmD, David L. DeRemer, PharmD, Dianna Howard, MD, Randy A. Brown, MD, Roger H. Herzig, MD, Val R. Adams, PharmD

Blood (2004) 104 (11): 5317.

https://doi.org/10.1182/blood.V104.11.5317.5317

Published: 2004

NARROW

TCA Cycle Inhibition By Cpi-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)

The Mitochondrial Metabolism Inhibitor Cpi-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone Is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML)

Feasibility of a Symptom-Adapted Physical Activity Intervention during Induction Chemotherapy for Older Adults with Acute Myeloid Leukemia (AML)

Is Rituximab Needed With High Dose Chemotherapy and Autologous Stem Cell Transplant When Patients With Non-Hodgkin’s Lymphoma Have Been Exposed To It?

MRP1 Plays a Role in Regulating Hematopoietic Stem Cell Oxidative Stress and Differentiation Via MRP1-Dependent Gsh Efflux

A Phase 2 Study of Bortezomib Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid Leukemia: A Children's Oncology Group (COG) Study

A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients

A Phase I Study of the Combination of Azacitidine, Cyclophosphamide, Vincristine, and Rituximab in Relapsed and Refractory Lymphoma

A Phase I study using Bortezomib with Weekly Idarubicin for the Treatment of Elderly (>60 YEARS) and Relapsed Patients with Acute Myeloid Leukemia (AML)

Gelclair® for the Treatment of Chemotherapy-Induced Stomatitis in Transplant and Hematology Patients: An Interim Analysis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only